About: Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 December 2000

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в грудні 2000 (uk) مقالة علمية تنشرت ف 1 دجنبر 2000 (ary) article scientifique publié en 2000 (fr) im Dezember 2000 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu n'avientu de 2000 (ast) scientific article published on 01 December 2000 (en)
publication date	wds:Q73365339-EA0289B2-F189-4246-9DDA-3ECBF4D57F2D
publication date	2000-12-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q73365339-B86DD65F-10BB-45F1-B339-BBDD5B9B3B03
language of work or name	English
cites work	wds:Q73365339-13F3501F-055C-4ACC-ACEA-C4476C0CE44E wds:Q73365339-1B343688-B680-4DA8-AEA2-B0C7C167B3FE wds:Q73365339-2A11373E-7870-4F64-9558-E5814C20057E wds:Q73365339-2E93C37B-747C-4698-9228-BA0051DD8008 wds:Q73365339-4D2483C1-30CD-418A-AA55-03586D42AA05 wds:Q73365339-4FC61A01-AE9F-45F8-8D16-9F28032E5D20 wds:Q73365339-6B3B8B09-B000-4AF5-82E7-2E22A09CBE97 wds:Q73365339-7BD33202-E107-48AD-B420-AB96751FB8F5 wds:Q73365339-883230F8-92A5-483A-BD00-369F5D022ECB wds:Q73365339-98159159-8694-40BA-A53C-0680DB7806CA wds:Q73365339-A16128CE-7DFA-4C12-A24B-F39A62DD612E wds:Q73365339-C46C33C7-A0DC-4D26-AB18-43EDAD316FF2 wds:Q73365339-CC6A477B-E22B-452F-A8F8-0474F7DFE981 wds:Q73365339-CC7B9BD3-0D29-43AB-8587-D10A55B77738 wds:Q73365339-CE43796C-B492-4DA6-9759-33CB704E7E38 wds:Q73365339-D1D7BE3D-E908-42E5-98FA-F072AD902773 wds:Q73365339-E1B415EF-E7F4-4718-89BA-71E2D1CB238C wds:Q73365339-E5FB43FA-2A91-4360-87B4-8559A0B0F9F3 wds:Q73365339-E779772B-3AB1-408A-BCBD-863EF6AFC905
cites work	Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade Myonecrosis after revascularization procedures Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate Improved clinical outcome after widespread use of coronary-artery stenting in Canada Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase The myth of the myocardial 'infarctlet' during percutaneous coronary revascularization procedures Economic issues in glycoprotein IIb/IIIa receptor therapy Design and methodology of the ESPRIT trial: evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention Stenting for ischemic heart disease
author name string	wds:Q73365339-80CC6FB1-BA32-4A48-BE89-A1073DD1C2F0
author name string	ESPRIT Investigators. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy
rdfs:label	Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial (en) Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial (nl)
skos:prefLabel	Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial (en) Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial (nl)
name	Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial (en) Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial (nl)
title	wds:Q73365339-4BC746CE-3220-430F-B804-B9974289B6DD
title	Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial (en)
page(s)	wds:Q73365339-2E6B9BDD-4B98-489D-A30C-4509BF4E0CE7
page(s)	2037-2044
instance of	wds:Q73365339-A0B1AEBC-DC88-40CA-8BF3-F186AC8A90E9
instance of	scholarly article
main subject	wds:Q73365339-6EFC4888-A0A1-4CFB-A6D2-47734A882212 wds:Q73365339-AD1D4EE3-99ED-4C60-BFAC-F719A8A83DFC
main subject	placebo placebo-controlled trial
PubMed ID	wds:Q73365339-E73C949C-A498-4765-9851-F4330162C9BE
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/11145489
PubMed ID	11145489
published in	wds:Q73365339-8C0CC49B-E4DB-4A94-AEB8-91EFF2FAC1EF
published in	The Lancet
issue	wds:Q73365339-A530DF33-C0E9-4848-9626-BFA48FEA6A26
volume	wds:Q73365339-477683F8-123B-40E2-91C2-D563319E9C4C
issue	9247
volume	356
DOI	wds:Q73365339-88C494E9-60EC-4B8D-9F91-19DA145BDC0F
DOI	http://dx.doi.org/10.1016/S0140-6736(00)03400-0
DOI	10.1016/S0140-6736(00)03400-0
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q73365339
is cites work of	Activated clotting times in the setting of eptifibatide use during percutaneous coronary intervention Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention Current concepts in the antithrombotic management of non-ST-elevation acute coronary syndromes Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial Association of eptifibatide and acute profound thrombocytopenia Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting Effectiveness of tirofiban, eptifibatide, and abciximab in minimizing myocardial necrosis during percutaneous coronary intervention (TEAM pilot study). Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials Long-term mortality benefit with the combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac events Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction wd:Q22241913 A pilot study of eptifibatide for treatment of acute pain episodes in sickle cell disease. Gender differences in clinical outcome after coronary artery stenting with use of glycoprotein IIb/IIIa inhibitors Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 193 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software